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AbstrAct
Objectives Ultrasmall superparamagnetic particles of 
iron oxide (USPIO)-enhanced MRI can detect tissue-
resident macrophage activity and identify cellular 
inflammation within tissues. We hypothesised that 
USPIO-enhanced MRI would provide a non-invasive 
imaging technique that would improve the diagnosis and 
management of patients with acute myocarditis.
Methods Ten volunteers and 14 patients with 
suspected acute myocarditis underwent T2, T2* and late 
gadolinium enhancement (LGE) 3T MRI, with further T2* 
imaging at 24 hours after USPIO (ferumoxytol, 4 mg/kg) 
infusion, at baseline and 3 months. Myocardial oedema 
and USPIO enhancement were determined within areas 
of LGE as well as throughout the myocardium.
results Myocarditis was confirmed in nine of the 
14 suspected cases of myocarditis. There was greater 
myocardial oedema in regions of LGE in patients with 
myocarditis when compared with healthy volunteer 
myocardium (T2 value, 57.1±5.3 vs 46.7±1.6 ms, 
p<0.0001). There was no demonstrable difference in USPIO 
enhancement between patients and volunteers even within 
regions displaying LGE (change in R2*, 35.0±15.0 vs 
37.2±9.6 s−1, p>0.05). Imaging after 3 months in patients 
with myocarditis revealed a reduction in volume of LGE, a 
reduction in oedema measures within regions displaying 
LGE and improvement in ejection fraction (mean −19.7 mL, 
95% CI (−0.5 to −40.0)), −5.8 ms (−0.9 to −10.7) and 
+6% (0.5% to 11.5%), respectively, p<0.05 for all).
conclusion In patients with acute myocarditis, USPIO-
enhanced MRI does not provide additional clinically 
relevant information to LGE and T2 mapping MRI. This 
suggests that tissue-resident macrophages do not 
provide a substantial contribution to the myocardial 
inflammation in this condition. Clinical trial registration 
NCT02319278; Results.
IntrOductIOn
Acute myocarditis comprises a wide clinical spec-
trum from subclinical disease to severe heart 
failure and is a major cause of sudden death in 
young adults.1 Pathologically, it is characterised 
by inflammatory cell infiltration of the myocar-
dium with evidence of myocyte necrosis that is not 
characteristic of an ischaemic aetiology.2 Causes of 
myocarditis include infections, immune-mediated 
injury and toxins (such as anthracyclines) although 
frequently no cause is identified.3
A variety of inflammatory cells infiltrate the 
myocardium during myocarditis. In viral myocar-
ditis, the infiltrate is predominantly lymphocyte 
rich, but other cells including plasma cells, neutro-
phils, eosinophils, giant cells and macrophages 
are also present.2 4–9 Monocytes differentiate into 
macrophages at sites of myocarditis, suggesting that 
they play an important role in the injury or repair 
of the myocardium.10
Endomyocardial biopsy is considered the gold 
standard investigation for diagnosis. However, this 
is prone to sampling error and is uncommon in 
routine clinical practice.3 Cardiac MRI plays a key 
role in the diagnosis and shows typical appearances 
on T2-weighted and late gadolinium enhance-
ment (LGE) imaging according to the Lake Louise 
Criteria.11 More recently, quantitative mapping 
techniques appear to improve diagnostic accuracy 
further.12
Iron oxide nanoparticles are generating 
interest as an MRI contrast agent able to detect 
macrophages, and clinical applications are now 
emerging.13–21 Ultrasmall superparamagnetic 
particles of iron oxide (USPIO) consist of an 
iron oxide core surrounded by a carbohydrate or 
polymer coating. They are small enough to extrav-
asate passively through capillaries, where they are 
engulfed by tissue-resident macrophages22 and are 
detectable by T2*-weighted MRI. Thus, USPIO-en-
hanced MRI can identify tissue-resident macro-
phage activity and identify cellular inflammation 
within tissues.
In a promising preclinical study of autoimmune 
myocarditis,23 iron nanoparticles were ingested by 
inflammatory cells and improved distinction of 
areas with severe inflammation on MRI compared 
with conventional T2-weighted and gadolinium-en-
hanced MRI. We aimed to assess and quantify 
myocardial USPIO enhancement in acute myocar-
ditis and to correlate enhancement with clinical 
measures of inflammation and oedema using 
T2 mapping and LGE MRI and compare these 
measures with healthy volunteers.24 We hypoth-
esised that USPIO-enhanced MRI would detect 
myocardial macrophage activity in myocarditis and 
provide a cellular-specific non-invasive imaging 
technique that may aid and improve patient diag-
nosis and management.
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MethOds
Patients were recruited from a single centre as part of an open-
label observational multicentre cohort study ( ClinicalTrials. gov 
(NCT02319278); Results). The study was performed in accor-
dance with the Declaration of Helsinki, the approval of the Scot-
land A Research Ethics Committee and the written informed 
consent of all participants. The Medicines and Healthcare prod-
ucts Regulatory Authority of the UK gave Clinical Trial Authori-
sation for the study (EUDraCT 2013-002336-24).
study populations
Adult (>18 years of age) patients with suspected acute 
myocarditis were recruited into the study. The clinical diag-
nosis was made by an independent clinical cardiologist based 
on the history, ECG, serum troponin (ARCHITECT STAT 
troponin I assay, Abbott Laboratories, Illinois, USA) and other 
available imaging modalities. The diagnosis of myocarditis 
was verified from case note review by an independent cardi-
ologist and retained for analysis if the MRI scan (reported 
and agreed by two independent radiologists) showed imaging 
features of myocarditis on LGE and/or T2 mapping.11 Healthy 
volunteers had no clinically significant medical history. Exclu-
sion criteria were contraindication to MRI or ferumoxytol 
infusion, any other inflammatory comorbidity, renal failure 
(estimated glomerular filtration rate <30 mL/min/1.73 m2), 
pregnancy, breast feeding and women of childbearing poten-
tial without reliable contraception.
study protocol
Patients with suspected myocarditis and healthy volunteers 
underwent paired MRI scans at baseline, and patients were 
invited to return for repeat imaging after 3 months.
MRI
MRI was performed using a MAGNETOM Verio 3T MRI 
scanner running software V.VB17 (Siemens Healthcare, 
Erlangen, Germany), with a dedicated cardiac array coil. All 
images were acquired using ECG-gated breath holds. Routine 
steady state free precession (TrueFISP) sequences were used to 
acquire long-axis and short-axis images of the heart. Oedema 
imaging was conducted using a Siemens T2 mapping based 
on a prototype T2-prepared TrueFISP acquisition acquiring 
identical long-axis and short-axis slice positions. Quantitative 
USPIO imaging was performed in similar slice positions using 
a prototype T2*-weighted multigradient-echo acquisition 
using a volumetric shim applied over the entire heart volume. 
Standard cardiac slice widths (6 mm width with 4 mm gap) 
and eight echo times (2.1–17.1 ms range) with matrix size of 
256×115 were acquired for T2* maps. The in-plane resolu-
tion differed as required for larger or smaller objects; gener-
ally, a field of view of 400×300 mm was used with an in-plane 
resolution of 2.6×1.6 mm. T2* relaxation times were calcu-
lated before and after administration of USPIO.
Immediately after the baseline T2, T2* and TrueFISP cine 
imaging, breath-held inversion recovery sequences in long-axis 
and short-axis planes were used to acquire late enhancement 
images following an intravenous administration of gadolinium 
contrast medium (0.1 mmol/kg; Gadovist, Bayer, Germany). 
Optimal inversion time (TI) was determined on a slice-by-slice 
basis using standard late-enhancement TI-scout protocols. The 
inversion-recovery late-enhancement short-axis slices were 
acquired using similar slice positions as the T2 and T2* imaging.
USPIO
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg; Rienso, 
Takeda Italia, Italy) was performed immediately following the 
baseline magnetic resonance scan over 15 min using a concen-
tration of 2–8 mg/mL, diluted in 0.9% saline or 5% dextrose. 
Haemodynamic monitoring was conducted throughout.
Image analysis
All T2*-weighted multigradient echo images for each patient 
were analysed using Circle CVI software (Circle CVI42, 
Canada). An experimentally determined threshold used in 
previous work14 for the coefficient of determination (r2>0.85) 
was used to exclude data that did not have an acceptable expo-
nential decay when signal intensity (SI) was plotted against echo 
time. Individual images affected by artefact were excluded. The 
inverse of the mean T2* (R2*) for each regions of interest (ROI) 
was then calculated to assess the uptake of USPIO, where the 
higher the value, the greater the USPIO accumulation.
Analysis of T2 maps, LGE and ventricular volume and func-
tion was also performed using Circle CVI software. T2 and T2* 
data were collected immediately prior to USPIO administration. 
USPIO-enhanced T2* data were collected 24–25 hour following 
ferumoxytol administration.
ROI selection
ROI were drawn using the standard 16-segment cardiac model25 
and panmyocardial values averaged using all 16 segments. As 
a final method of analysis to focus on inflamed myocardium, 
regions with contiguous LGE>1 cm2 on a single short-axis slice 
were retained and visually coaligned with corresponding T2 and 
T2* images. These corresponding coaligned regions were then 
averaged to form LGE+T2 and T2* regions.
statistical analysis
All statistical analysis was performed with GraphPad Prism V.6 
(GraphPad Software, San Diego, California, USA). Shapiro-Wilk 
normality testing was carried out prior to testing. To compare 
USPIO uptake and myocardial oedema in patients and volun-
teers, R2* and T2 values were compared using paired and 
unpaired t-tests, Mann-Whitney and Wilcoxon tests depending 
on pairing and normality of data. To compare results at 3 months 
with baseline, a paired t-test was used. Statistical significance was 
defined as two-sided p<0.05.
results
Ten volunteers and 14 patients with suspected myocarditis were 
recruited. Nine patients had confirmed myocarditis according to 
imaging criteria and independent review. Baseline imaging was 
conducted within a week of diagnosis. Four patients had alter-
native diagnoses (takotsubo cardiomyopathy (n=2), lung cancer 
(n=1), polymyositis (n=1)) and one patient had an incidental 
finding of an unknown chest wall metallic implant. These five 
patients were excluded from further analysis. All nine patients 
retained for analysis had typical features of myocarditis on LGE 
imaging. Of these nine patients, one patient did not return at 
baseline for the 24 hours post-USPIO scan. Seven of the nine 
patients returned at 3 months for repeat imaging.
The healthy volunteer group was older with greater ejection 
fraction than the myocarditis group at baseline (p<0.001 for both, 
table 1). Patients with myocarditis had greater neutrophil count, 
C-reactive protein (CRP) and serum troponin concentrations 
than volunteers (p<0.05, p<0.01 and p<0.0001, respectively). 
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There were no other significant differences between participant 
groups at baseline.
Administration of ferumoxytol was well tolerated with no 
adverse reactions reported during or immediately after adminis-
tration in any of the participants.
usPIO enhancement
At baseline, there were no differences in R2* values between 
healthy volunteers and patients with myocarditis (panmyocar-
dium and LGE+ regions; Figures 1, 2). After USPIO adminis-
tration, the R2* in all three groups increased but there was no 
difference in either the change in or post-USPIO, R2* between 
the groups (figure 2 and table 2).
Myocardial oedema
There was no difference in panmyocardial T2 between volun-
teers and patients with myocarditis. Regions displaying LGE in 
myocarditis patients had higher T2 than panmyocardial values 
for both healthy volunteers and patients with myocarditis 
(p<0.0001 and p<0.01, respectively; figure 2 and table 2).
baseline versus 3-month imaging in patients with myocarditis
There were no changes in myocardial USPIO uptake between 
baseline and 3 months either on panmyocardial analysis 
(mean +7.6 s−1 95% CI (−4.8 to 19.9)) or in regions with LGE 
(−4.2 s−1 (−21.9 to 13.5), p>0.05 for both; figure 3). Panmyo-
cardial T2 did not change over 3 months (−1.1 (-5.8 to 3.5), 
p>0.05). Volume of LGE and T2 within regions displaying LGE 
reduced over the 3-month period (−19.7 mL (−0.5 to −40.0) 
and −5.8 ms (−0.9 to −10.7), respectively, p<0.05 for both). 
Ejection fraction increased over the 3-month period (+6% (0.5 
to 11.5), p<0.05).
dIscussIOn
For the first time, we report the combined assessment of myocar-
ditis using LGE, T2 mapping and USPIO-enhanced T2* MRI. 
USPIO-enhanced T2* MRI has previously been used in man to 
assess cardiovascular inflammation in a range of different condi-
tions,14 16 21 26 with preliminary positive results from a rodent 
model of myocarditis. This raised hope that USPIO-enhanced 
T2*MRI might add useful cell-specific clinical information in 
patients with myocarditis. However, while we found typical 
features of myocarditis using standard imaging with LGE and 
table 1 Participant characteristics
healthy 
volunteers
Myocarditis 
(baseline)
Myocarditis
(3 months)
Number 10 9 7
Female 6 1 1
Age (years) 50 (45–53) 28 (24–34)*** 25 (23–35)
Body mass index (kg/m2) 26 (23–29) 25 (22–29) 25 (22–27)
Left ventricular ejection 
fraction (%)
61.1±4.1 51.0±4.9*** 57.1±4.3
Late gadolinium 
enhancement (mL)
Nil 30.3±19.3 16.3±12.3
ECG n/a 9/9
  ST elevation 7
  T-wave inversion 1
  Normal 1
Coronary angiogram n/a 4/9
  Normal 4
Echo n/a 8/9
  Wall motion 
abnormality
4
  Normal 4
Blood tests
  White cell count 
(×109/L)
5.8 (4.2–7.1) 7.1 (6.1–8.9) 5.1 (4.6–5.6)
  Neutrophil count 
(×109/L)
3.2 (2.2–4.2) 4.4 (3.7–5.2)* 2.8 (2.7–3.5)
  Lymphocyte count 
(×109/L)
1.7 (1.4–2.1) 1.8 (1.3–2.2) 1.8 (1.2–1.9)
  Monocyte count 
(×109/L)
0.4 (0.3–0.7) 0.6 (0.5–0.8) 0.4 (0.3–0.5)
  C-reactive protein 
(mg/L)
1.0 (1.0–2.5) 38(14-63)** 2.0 (1.0–2.0)
  Troponin (ng/L) 2.0 {1.5–4.0) 1 21 842 (3950–
25 722)****
4.0 (2.0–6.0)
Mean±SD or median (IQR).
* p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 (compared with volunteers at 
baseline).
Figure 1 Images of patient with myocarditis. Three chamber and 
basal short-axis images of a patient with myocarditis displaying patchy 
posterolateral late gadolinium enhancement (LGE) (white regions, 
arrowed) that correspond to oedematous regions of myocardium on 
the T2 map (lighter regions, arrowed). There is no uptake of ultrasmall 
superparamagnetic particles of iron oxide (USPIO) in the post-USPIO 
R2* maps; corresponding regions may even have lower R2* in this 
patient. Myocardial oedema appears to normalise but subtle LGE 
remains at 3 months.
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T2 mapping cardiovascular magnetic resonance (CMR), we did 
not detect USPIO enhancement within the myocardium of our 
patients. This suggests that USPIO-enhanced MRI provides no 
additional diagnostic value in these patients and that tissue-res-
ident macrophages are not a major contributor to the cellular 
inflammation following acute myocarditis.
Our case study population of nine patients were excellent 
examples of myocarditis. They were young, with significantly 
elevated levels of systemic inflammatory markers, including 
neutrophil count, CRP and cardiac-specific high-sensitivity 
troponin, and all had typical features of myocarditis on CMR 
reported by two independent clinical radiologists. Most patients 
had ECG changes suggesting significant myocyte injury and 
several had normal coronary angiograms. All patients that did 
not have a coronary angiogram did not have any risk factors for 
coronary artery disease. We detected MRI features of myocar-
ditis in every patient. LGE was discontinuous in nature and 
generally epicardial and subepicardial in distribution, but could 
be found in the midwall and occasionally in the subendocar-
dium. LGE was never found in the subendocardium alone or 
confined to one coronary territory that would be more sugges-
tive of myocardial infarction. In keeping with the typical distri-
bution of myocarditis, most patients displayed LGE in the infe-
rior, posterior and lateral walls. We are therefore confident that 
the diagnosis of myocarditis was robust in all patients, and an 
independent cardiologist verified this.
Myocardial oedema was easily visualised, and indeed quan-
tified, using T2 mapping (Figure 2). We found intense myocar-
dial oedema in our myocarditis cohort with maximal T2 
values approaching 70 ms on T2 mapping. Within regions 
displaying LGE (LGE+), there was a profound increase in T2 
when compared with volunteers. This signal was so powerful 
that a trend remained evident when comparing panmyocardial 
T2 values to those of volunteers, although the difference was 
not statistically significant. Seven patients returned for repeat 
imaging assessment at 3 months, where we recorded an improve-
ment in clinical features: a reduction in the volume of LGE (by 
around 50%), a reduction in oedema within inflamed (LGE+) 
regions and an overall improvement in ejection fraction.
We were unable to detect USPIO accumulation in our cohort 
of patients with myocarditis. We know that macrophages can 
be present in myocarditis, although they are generally not the 
predominant cell type. It is possible that patients within our 
group had predominantly lymphocytic or neutrophil-rich cell 
infiltrate and the finding of greater levels of neutrophils in 
patients with myocarditis at baseline may support the latter. The 
clinical care team did not feel that endomyocardial biopsy was 
justified in any of the cases, and lack of histological data is clearly 
a limitation. In recent work, we have detected USPIO-laden 
macrophages in patients with recent myocardial infarction and 
demonstrated macrophage uptake of USPIOs in biopsies taken 
at the time of cardiac surgery.13 We therefore acknowledge that 
while some USPIO-laden macrophages may have been present in 
patients with myocarditis, there were either insufficient numbers 
of macrophages or USPIO engulfment was inhibited or deficient. 
Ultimately, USPIO-enhanced T2* CMR was unable to demon-
strate increased macrophage activity and lacked sensitivity for 
detecting myocarditis.
A further contributory reason for failure to detect USPIO 
enhancement within inflamed regions may be due to diffi-
culties encountered in USPIO-enhanced T2* imaging. These 
are discussed in greater detail elsewhere,24 but artefact due 
to breathing and in particular, ‘blooming’ artefacts from the 
vascular organs of the lungs, liver and stomach can be prob-
lematic. This can make analysis more challenging by having 
to exclude the affected later echo times from T2* decay curve 
fitting. Indeed, ‘blooming’ artefacts from nearby tissues and 
organs most commonly affect the inferior and lateral walls, 
Figure 2 Myocardial USPIO enhancement vs Oedema at Baseline. Changes in myocardial R2* due to USPIO accumulation (A, left) and myocardial 
oedema by T2 mapping (B, right) are shown in healthy volunteers (HV) and patients with myocarditis (M) using panmyocardial average, and further 
limited to regions displaying LGE in patients with myocarditis (M LGE+).There were no significant differences in ΔR2* due to USPIO accumulation 
between all groups (p>0.05 for all). There was no difference in panmyocardial T2 between volunteers with patients with myocarditis. Myocardial 
regions displaying LGE (M LGE+) had greater T2 than the panmyocardial value for healthy volunteers and myocarditis patients (****p<0.0001 and 
**p<0.01 respectively).
table 2 Myocardial R2* and T2 values in healthy volunteers and 
patients with myocarditis
healthy volunteers
(panmyocardial)
Myocarditis
(panmyocardial)
Myocarditis
(lGe+ regions)
Panmyocardial pre-
USPIO R2*
(s−1)
46.9±4.1 43.7±5.3 51.8±8.3
Panmyocardial post-
USPIO R2*
(s−1)
84.2±12.4 75.6±11.3 86.1±15.3
Panmyocardial 
ΔR2* (s−1)
37.2±9.6 31.4±7.5 35.0±15.0
T2 (ms) 46.7±1.6 48.9±3.1 57.1±5.3****
Mean±SD.
****p<0.0001 (compared with volunteers).
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which is the usual site of inflammation in myocarditis. There-
fore, the myocardial regions of greatest interest were often the 
most difficult to analyse although this can usually be overcome.24 
This may go some way to explain why there is greater spread 
of R2* data in patients with myocarditis, especially in LGE+ 
regions. Finally, patients with myocarditis often had symptoms 
of pleurisy and pericarditis, and despite adequate analgesia, 
often found the long breath holding required for T2* imaging 
difficult.
Some final limitations also deserve mention. First, the sample 
size was small, but numbers in this pilot study were sufficient 
to show that USPIO-enhanced T2* CMR fails to add clinically 
relevant information to CMR imaging parameters of LGE and 
T2 mapping for individual patients. Second, the control volun-
teer group was not age or sex matched but we have no reason 
to believe that this influenced the results. Lastly, myocardial 
geometry is affected by several factors that vary between scans 
such as the presence of tissue oedema, heart rate and blood 
volume status and accurate coregistration can be challenging.
Despite these results, USPIO-enhanced imaging still holds 
promise as a non-invasive imaging method for the diagnosis and 
monitoring of tissue inflammatory macrophages in the heart. 
We have recently found that USPIO-enhanced MRI can detect 
and serially monitor macrophages after myocardial infarction 
(MI)13 and work is under way at our centre as part of this project 
(NCT02319278) to assess the value of this technique in diag-
nosing cardiac sarcoidosis and cardiac transplant rejection. If 
successful, USPIO-enhanced MRI may provide a platform on 
which to assess existing and novel therapeutic interventions that 
might modify the inflammatory process, not only after MI but 
also in other inflammatory processes affecting the heart.
In conclusion, we have shown that in patients with acute 
myocarditis, USPIO-enhanced T2* MRI does not provide addi-
tional clinically relevant information to that of LGE and T2 
mapping MRI. This suggests that tissue-resident macrophages do 
not provide a substantial contribution to the myocardial inflam-
mation in this condition.
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Key messages
What is already known about this subject?
Ultrasmall superparamagnetic particles of iron oxide (USPIO) are 
ingested by tissue macrophages that can be visualised using MRI 
to highlight areas of inflammation within the heart.
What does this study add?
USPIO-enhanced T2* MRI does not provide additional clinically 
relevant information to that of LGE and T2 mapping MRI. This 
suggests that tissue-resident macrophages do not provide a 
substantial contribution to the myocardial inflammation in this 
condition.
how might this impact on clinical practice?
USPIO-enhanced T2* MRI may still prove to be of value in 
diagnosing and monitoring conditions with macrophage-
driven myocardial inflammation, but its role in assessing acute 
myocarditis appears limited.
Figure 3 Changes on repeat imaging at 3 months in patients with myocarditis. There was no significant (ns) difference in ultrasmall 
superparamagnetic particles of iron oxide uptake between baseline and 3 months in both panmyocardium (A) and in regions displaying late 
gadolinium enhancement (LGE) (B). There was no difference in panmyocardial T2 (C) over 3 months. T2 in regions displaying LGE (D) reduced, as did 
the volume of LGE (E) over the 3-month period. There was an increase in ejection fraction (EF) between baseline and 3 months (F); *p<0.05.
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